UBS Group’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

UBS Group’s Portfolio CRXT Stock Details CRXT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-23,534	Closed	-$9K	–	11711
2022 Q2	$9K	Sell	23,534 -43,003	-65%	-$30.1K	﹤0.01%	8253
2022 Q1	$99K	Buy	66,537 +20,906	+46%	+$26.6K	﹤0.01%	5930
2021 Q4	$111K	Buy	45,631 +6,977	+18%	+$30.3K	﹤0.01%	6230
2021 Q3	$206K	Buy	38,654 +35,546	+1,144%	+$320K	﹤0.01%	5292
2021 Q2	$31K	Buy	+3,108	New	+$31.3K	﹤0.01%	6922

Other funds holding CRXT

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

UBS Group's CRXT Position: Q3 2022 in Review

UBS Group sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q3 2022, closing a stake of 23,534 shares — an estimated $9K sold.

UBS Group first reported a position in CRXT in Q2 2021 and held it in 5 quarters. The position peaked at $206K in Q3 2021. 2 funds tracked by Wall St. Rank hold CRXT as of Q3 2022.

UBS Group reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
UBS Group sold 23,534 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q3 2022, an estimated $9K.
UBS Group first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
UBS Group's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $206K in Q3 2021.
2 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on UBS Group's 13F filing for Q3 2022, filed 10 Nov 2022.